Breaking News, Collaborations & Alliances

Oxford Acquires ABL Europe from Institut Mérieux for €15M

Provides Oxford Biomedica with multi viral vector CDMO capabilities.

Oxford Biomedica plc, a cell and gene therapy contract development and manufacturing organization (CDMO), has entered into a sale and purchase agreement with TSGH SAS, a subsidiary of Institut Mérieux SA, for the acquisition of ABL Europe SAS. The acquisition for a consideration of €15 million, includes the value of €10 million, of pre-completion cash funding from Institut Mérieux in ABL Europe. Completion of the transaction is currently expected to take place in the first quarter of 2024....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters